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CLD :  Chronic liver disease 
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HDL :  High Density Lipoprotein 
CT Scan :  Computerized Tomography 
HBV Ag :  Hepatitis B Virus Antigen 
HCV :  Hepatitis C Virus 
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INTRODUCTION 
 
 “Is life worth living? It all depends on the liver “ quoted the well known 
American philosopher William James (1842 – 1910) 
 
 The liver is the largest organ in the body1 and one of the most complex 
functioning organs with a wide array of functions.   
 It plays a major role in carbohydrate, protein, lipid metabolism; inactivation of 
various toxins, metabolism of drugs, hormones, synthesis of plasma proteins & 
maintenance of immunity (Kupffer cells). 
 Right from being a primary site of haematopoiesis in fetal life to maintenance 
of hematological parameters in postnatal life; the liver has an extremely important 
role in maintenance of blood homeostasis.  
 It acts as a storage depot for Iron, Folic acid & Vitamin B12, secretes clotting 
factors and inhibitors. Hence it’s not surprising to see a wide range of hematological 
abnormalities in liver diseases. 
 In chronic liver disease the presence of jaundice, liver cell failure, portal 
hypertension and hypersplenism, reduced red cell half- life all influence peripheral 
blood picture2.  Both Liver cell failure & cholestasis can derange the coagulation 
system. Dietary deficiencies, bleeding, alcoholism and abnormalities in hepatic 
synthesis of proteins used for blood formation or coagulation add to the problem liver 
disease3. 
 This study was undertaken to describe the hematological abnormalities in 
decompensated chronic liver disease so that measures could be taken to correct them 
and reduce morbidity. 
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AIM OF THE STUDY 
 
1. To assess the hematological abnormalities in decompensated chronic liver 
disease 
2. To detect RBC abnormalities in patients with decompensated chronic liver 
disease 
3. To determine severity, morphology & most common type of anemia in 
chronic liver disease. 
4. To perform iron studies and to determine the most common type of anemia. 
To correlate ferritin and transferrin levels with the severity of liver disease. 
5. To determine folic acid levels in cirrhosis 
6. To determine Vitamin B12 levels and correlate with the severity of liver 
disease 
7. Quantitatively assess WBC abnormalities 
8. To detect platelet abnormalities in decompensated chronic liver disease  
9. To assess the coagulation profile of patients with decompensated chronic liver 
disease. 
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REVIEW OF LITERATURE 
 
 The liver is the largest organ in the body comprising 1/50th of the total adult 
body weight4. The median liver weight is 1,800 g in men and 1,400 g in women5. It is 
relatively larger in infants being about 1/18th of the total body weight. Sheltered by 
the ribs in the right upper quadrant, it consists of two anatomical lobes – right and 
left, the right lobe being about 6 times larger than the left. 
 
Figure 1: ANATOMICAL LOBES OF LIVER 
 The liver has a dual blood supply6 – the portal vein rich in nutrients brings 
venous blood from the intestines and spleen. The hepatic artery, a branch of the celiac 
axis supplies oxygen rich blood to the parenchyma. A functional anatomy is 
recognized based upon vascular and biliary anatomy.  The Couinaud classification7 
defines eight segments while the Bismuth classification8 defines 4 sectors. Using this 
definition the functional right and left lobes are divided by a plane running through 
the gall bladder fossa inferiorly and the groove for the IVC posteriorly.The main 
portal vein divides into right and left branches and each gives a branch to the 8 
functional segments. 
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Figure 2: COUINAUDS SEGMENTS OF LIVER 
   The right anterior sector contains segments V & VIII, the right posterior sector 
VI & VII. The left lateral sector contains segments II & III, the left medial sector 
being segment IV. Segment I the equivalent of the caudate lobe does not derive blood 
directly from the major portal branches or drain by any of the 3 major hepatic veins. 
This functional classification allows interpretation of radiological data and is of 
importance to the surgeon planning a liver resection. 
 
MICROANATOMY OF THE LIVER 
 There are approximately 202 * 103 cells in each mg of normal human liver, of 
which 171 * 103 is parenchymal and 31 * 103 littoral (sinusoidal including Kupffer 
cells) 9.  Many models of liver substructure have been proposed, the most popular of 
these is the hepatic lobule by Kiernan10 in 1883. He described circumscribed 
hexagonal lobules centered on the terminal vein with cords of hepatocytes radiating 
out to the portal tracts located at each pole.  
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FUNCTIONS OF THE LIVER 
 Impressed by the molding against adjacent organs, William Osler quipped that 
the liver was present only for packing purposes12!  
 Quite the contrary, the liver being the largest organ in the body is also the 
most versatile and functionally heterogeneous organ with a wide array of functions 
absolutely essential for life.   
Table 1: FUNCTIONS OF LIVER13 
 
 
 
 
1. Formation & secretion of bile 
2. Nutrient and vitamin metabolism 
- Glucose and other sugars 
- Amino acids 
- Lipids: fatty acids, cholesterol, 
lipoproteins 
- Fat soluble vitamins 
- Water soluble vitamins 
3.  Inactivation of various substances 
- toxins  
- drugs 
- steroids 
- other hormones 
- urea cycle 
 
 
4. Storage function 
    - Glycogen storage 
    - Lipid storage 
    - B12 and folate storage 
   - Fat & water soluble vitamins 
5. Synthesis of plasma proteins 
     - Acute phase proteins 
     - Albumin 
     - Clotting factors 
     - Steroid binding and other hormone 
binding proteins  
     - Fibrinogen, alpha-1 antitrypsin, 
ceruloplasmin, Haptoglobins & 
Complement system 
6. Immunity 
     - Kupffer cells 
     - Immunoglobulin – IgG, IgA, IgM 
     - Complement system 
 7 
 
CIRRHOSIS 
 Cirrhosis is the end result of the fibrogenesis that occurs with chronic liver 
injury/disease. It is defined anatomically as a diffuse process with fibrosis and nodule 
formation, characterized by 3 main morphological features14 
- Bridging fibrous septa connecting portal tracts with one another and with the 
terminal hepatic veins. 
- Parenchymal nodules representing regenerating nodules of hepatocytes 
- Disruption of liver architecture  
In clinical terms cirrhosis may be described as being decompensated or 
compensated15 
Compensated Cirrhosis: 
                     Many patients are found to have abnormal liver tests during routine 
medical or preoperative examinations; the liver test abnormalities being relatively 
minor. On physical examination the detection of an unexpected hepatomegaly or 
splenomegaly may trigger further investigations. 
Decompensated Cirrhosis: 
                      Decompensation means cirrhosis complicated by one or more of the 
following features: jaundice, ascites, hepatic encephalopathy or bleeding varices. 
Ascites is usually the first sign. Hepatorenal syndrome, hyponatremia and 
spontaneous bacterial peritonitis are also features of Decompensation but in these 
patients ascites invariably occurs first. 
 This clinical distinction has major implications for prognosis and treatment. 
Compensated cirrhosis has 50% survival at 10 years compared to 50 % survival at 18 
months for decompensated cirrhosis16. 
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CHRONIC LIVER DISEASE 
 Liver disease lasting for more than 6 months is called chronic liver disease 
manifesting pathologically as cirrhosis. 
AETIOLOGY-
CIRRHOSIS 
 
 
 
 
 
Table 2: Causes of cirrhosis17 
• Alcoholic cirrhosis 
• Post necrotic / post infective HCV, 
HBV, HBV & HDV 
• Non alcoholic steatohepatitis 
• Autoimmune hepatitis 
• Biliary tract diseases –  
primary biliary cirrhosis, 
secondary biliary cirrhosis, 
primary sclerosing cholangitis etc. 
• Metabolic disorders: 
- Wilsons disease 
- Hemochromatosis 
- Alpha 1 Anti Trypsin deficiency 
- Glycogen storage diseases 
- Cystic fibrosis 
- Galacatosemia 
- Hereditary fructose intolerance 
- Hereditary tyrosinemia 
- Ornithine transcarboymylase 
deficiency 
• Cardiac cirrhosis 
 
• Chronic Budd Chiari syndrome 
 
• Veno-occlusive disease 
 
• Sarcoidosis 
 
• Indian Childhood cirrhosis 
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PATHOGENESIS 
 The hepatic stellate cell is the principal cell involved in fibrogenesis18. 
Normally they lie within the space of Disse and are vitamin A storing cells. With 
sustained injury due to any cause, under the influence of various cytokines it 
transforms into a myofibroblast like cell which lays down type I & III collagen in the 
space of Disse and periportal areas. Continued injury leads to perpetual deposition of 
collagen and fibrosis accompanied by regeneration of hepatocytes in the form of 
regenerative nodules surrounded by fibrous scars resulting in cirrhosis. 
 
 
Figure 6: Hepatic Fibrogenesis19 
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CLINICAL EFFECTS OF CIRRHOSIS 
 
 The Clinical manifestations of chronic liver disease are due to portal 
hypertension and liver cell failure20. 
 
 
Figure 7: Clinical effects of Cirrhosis: courtesy21 Elsevier 2006 
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Table 3: STIGMATA OF CHRONIC LIVER DISEASE22 
FACE 
-Frontal balding 
-Pallor 
-Jaundice 
-Parotid enlargement 
-Madarosis 
-Xanthelasma 
-Telangiectasia / paper money skin 
-Cirrhotic facies 
-Signs of vitamin deficiencies 
-Fetor hepaticus 
HANDS 
-Palmar erythema 
-Flapping tremor 
-Leuconychia 
-Clubbing 
-Dupytrens contractures 
SKIN 
-Bruising 
-Spider nevi 
-Scanty body hair 
-Pigmentation 
NUTRITION 
-Glossitis 
-Angular stomatitis 
-Bitot spots 
-Muscle wasting 
-Anemia 
ENDOCRINE 
-Gynecomastia in men 
-Breast atrophy in women 
-Testicular atrophy 
-Impotence 
 
FEATURES OF PORTAL 
HYPERTENSION 
-Splenomegaly 
-Ascites 
-Collaterals – abdominal wall, 
esophageal, anorectal collaterals. 
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ROLE OF THE LIVER IN HAEMATOPOIESIS 
 In prenatal life, the liver acts as a primary site of haematopoiesis along with 
the spleen. Peak hepatic haematopoiesis occurs at about the 4 to 5th month of 
gestation, declines thereafter and stops by the 8 to 9th month when the bone marrow 
takes over. In postnatal life, it continues to play a key role in supporting 
haematopoiesis23. In certain pathological states (myeloproliferative disorders, 
Thalassemia) the liver rekindles its role as a primary haematopioetic organ24. 
 Though 85 to 90 % of the Erythropoietin is secreted from the peritubular 
interstitial cells of the kidney, the remaining 10 to 15 % is secreted from the liver25.  
It acts as a storage depot for folic acid and vitamin B1226, which is necessary for RBC 
and WBC maturation. By secreting Transcobalamine II27, it helps in transporting B12 
from the site of absorption and storage to haematopioetic cells in the marrow. The 
liver plays an important role in Iron metabolism. Transferrin is an iron transporting 
protein secreted by the liver28, which transports Iron from the site of absorption to the 
bone marrow for haemoglobin and RBC synthesis.   
 It regulates iron absorption by secreting Hepcidin; a molecule that down 
regulates Ferroportin and reduces Iron absorption; Anemia, hypoxia and low iron 
stores reduces Hepcidin production and thus enhances iron absorption29.   
 The liver is a primary reticuloendothelial organ containing plenty of Kupffer 
cells, which are an intrinsic part of the innate immune system and one of the most 
important Antigen presenting cells.  
 Thrombopoietin30 is a protein secreted by the liver that stimulates platelet 
synthesis. 
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 The coagulation cascade is essentially a multiplying series of enzymatic 
conversions40 involving a cascade of clotting factors culminating in the formation of a 
definite fibrin clot. All clotting factors are synthesized in the liver except Von Willi 
Brand factor & Factor VIII. The vitamin K dependent factors41 are II, VII, IX, X; 
these factors undergo Gamma carboxylation of glutamic acid residues to form the 
active molecules in the liver. 
 There are 2 major pathways by which prothrombin is converted to thrombin, 
the intrinsic and the extrinsic pathways42. 
 The intrinsic pathway is initiated by the activation of the Hageman factor, or 
factor XII. 
 Wettable surface, such as glass, powdered diatoms; micelles of long chain 
fatty acids and collagen fibers are capable of activating the Hageman factor. 
 Once factor XII is activated it initiates a series of reactions in which the 
varying blood-clotting factors are sequentially converted from their precursor form to 
their active or enzymatic form.  
 Thus, activated factor XII activates factor XI, or plasma thromboplastin 
antecedent, which in turn activates factor IX, or the Christmas factor, which in turn 
activates factor VIII, or the antihemophilic factor. Activated factor VIII then activates 
factor X, known as the Stuart factor. 
  Activated factor X in the presence of coagulation factor V and platelet lipids 
converts prothrombin to thrombin. 
 Once thrombin is generated it converts fibrinogen to fibrin monomers, which 
spontaneously polymerizes. However, this polymer is weak and can easily dissociate.  
 17 
 
 Under the influence of factor XIII, this loose polymer is transformed by the 
formation of covalent cross-links into a dense, irreversible aggregate that is called the 
definitive hemostatic plug. 
 The extrinsic pathway is another mechanism by which prothrombin may be 
activated.  
 Many tissues like endothelium lined blood-vessel walls, lung and brain, 
contain a lipid-protein complex directly capable of activating factor X in the presence 
another cofactor called factor VII.  
 Activated factor X then converts prothrombin to thrombin and then follows 
suit, through to the final common pathway leading to the formation of the fibrin rich 
definitive hemostatic plug.  
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added to the mixture to initiate clotting; the time needed for a fibrin clot to form is 
measured. 
 The Activated partial thromboplastin time assess the function of the Intrinsic 
pathway namely factors XII, XI, IX, VIII, X, V, II & fibrinogen. In this assay, clotting 
is initiated by the addition of wetting surfaces like ground glass, which then activates 
Hageman’s factor, phospholipids and calcium& the time taken for a fibrin clot to 
form is noted. 
 Once activated, the coagulation cascade is restricted to the site of vascular 
damage, to prevent excessive run away clotting in the vascular compartment;  
3 categories of endogenous anticoagulants45prevent clotting. 
• Anti Thrombin III inhibits activity of thrombin and other serine proteases – 
IXa, Xa, XIa and XIIa. Anti thrombin III is activated by heparin like 
molecules and hence the action of heparin as an anticoagulant. 
• Protein C & S – Vitamin K dependent endogenous anticoagulants that act in a 
complex that proteolytically inactivated Factor Va & VIIIa. 
• TFPI – Tissue factor pathway inhibitor inactivates tissue factor – VII 
complexes. 
 Once the coagulation cascade has accomplished its mission of preventing 
blood loss through formation of a fibrin clot, it then sets into motion the activation of 
a fibrinolytic cascade46 mediated by plasmin that cleaves the fibrin clot and restores 
blood flow. The resultant Fibrin degradation products most notably fibrin derived D-
Dimers have weak anticoagulant activity. 
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Figure 12: Fibrinolysis:47 
Thus we see that the liver plays an essential role in all stages of haemostasis.  
• Through the synthesis of Thrombopoietin, it stimulates platelet synthesis 
whose main function is the formation of the primary haemostatic plug. 
• All clotting factors except VWF & VIII are synthesized in the liver. 
Activation of the clotting factors through a waterfall cascade leads to the 
formation of the definitive haemostatic plug. 
• Liver is the site of Vitamin K storage, which is needed for the 
posttranslational gamma carboxylation glutamic acid residues of coagulation 
factors II, VII, IX & X. Vitamin K is also required for the synthesis of 
endogenous anticoagulants – protein C & S.I 
• Inhibitors of coagulation, that is endogenous anticoagulants are also 
synthesized in the liver – Antithrombin III, Protein C & S. 
• The liver also synthesizes plasmin inhibitors such as Alpha 2 Anti plasmin 
and Tissue Plasminogen Activator inhibitor. 
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IRON METABOLISM 
 An average persons diet48 contains about 10 to 20 mg of iron, most in the form 
haeme contained in animal products, while remainder being inorganic iron in 
vegetables. About 20 % of the haeme iron is absorbable in contrast to 1 to 2 % ofnon- 
haeme iron.The total body iron content can be divided into functional and storage 
compartments. 
 
   Table 4: IRON DISTRIBUTION IN ADULTS 49: COURTESY ROBBINS PATHOLOGY 
 
 About 80% of the functional iron is found in haemoglobin, myoglobin and 
iron containing enzymes such as catalase & cytochromes.  
 The storage pool represented by haemosiderin and ferritin contains about 15 to 
20% of total body iron, females in the reproductive age having less due to menstrual 
blood loss. Iron in the body is recycled extensively between the functional and storage 
pools. 
 
POOL MEN WOMEN 
TOTAL 3450 mg 2450 mg 
FUNCTIONAL POOL 
HAEMOGLOBIN 
MYOGLOBIN 
ENZYMES 
 
2100mg 
300mg 
50mg 
 
1750mg 
250mg 
50mg 
STORAGE POOL 
FERRITIN, HEMOSIDERIN 
1000mg 400mg 
  
Figure 1
22 
3: Iron metabolism50 
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regulating Ferriportin. Hence when iron stores are adequate the liver produces more 
hepcidin and when iron stores are inadequate it decreases hepcidin. By inhibiting 
ferriportin, hepcidin not only reduces iron uptake from enterocytes but also 
suppresses iron uptake from macrophages, which are an important source of the iron 
that is used by RBC precursors to make haemoglobin. Hepcidin production is 
stimulated by IL-6; hence during long standing inflammation iron utilization is 
decreased explaining the basis of anemia of chronic disease. 
 Interpretation of various parameters of iron metabolism should always be done 
against the clinical background of the patient.  
 Hepatic parenchymal cells contain appreciable amounts of ferritin, and it is 
known that liver disease can affect the serum ferritin levels regardless of any change 
in iron stores. 
Table 5: Iron studies interpretation58 
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B12 METABOLISM 
 Vitamin B12 is a complex organometallic compound known as cobalamine59.  
Under normal circumstances humans are totally dependent on dietary vitamin B 12. 
Plants & vegetables contain little cobalamine; humans are dependent on animal 
sources for B12.  
 The daily requirement is 1 to 3 ug per day. Body stores are 2 to 3 mg, 
sufficient for 3 to 4 years if supplies are completely cut off60. 
• Vitamin B12 is freed from binding proteins in food through the action of 
pepsin in the stomach and binds to salivary proteins called haptocorrins or R 
Binders. 
• In the duodenum, bound vitamin B12 is released by the action by the action of 
pancreatic proteases. It then associates with Intrinsic factor. 
• This complex is transported to the ileum where it is endocytosed by ileal 
enterocytes through cubulin receptors. 
• With ileal cells, vitamin B12 associates with a major carrier protein 
Transcobalamine II (synthesized by the liver)61 and is secreted into plasma. 
Transcobalamine II delivers vitamin B12 to the liver and other cells of the 
body, including rapidly proliferating cells in the bone marrow and 
gastrointestinal tract. 
• Between 0.5 to 5 ug of cobalamine enter the bile acid each day. This binds to 
IF, hence a major portion of biliary cobalamine normally is reabsorbed 
together with cobalamine derived from sloughed intestinal cells. Because of 
the appreciable amount of cobalamine undergoing enterohepatic circulation, 
cobalamine deficiency develops more rapidly in individuals who malabsorb 
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B12 than it does in vegans, in whom reabsorption of biliary cobalamine is 
intact. 
 
Figure 16: B12 metabolism62 
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 Cobalamine exists in a number of different chemical forms. All have a cobalt 
atom at the centre of a corrin ring. In nature, the vitamin is mainly in the 2-
deoxyadensoyl form, located chiefly in the mitochondria. It is the cofactor for the 
enzyme Methyl Malonyl CoA mutase. The other major natural cobalamine is 
methylcobalamine, the form in human plasma and in cell cytoplasm. It is the cofactor 
for methionine synthase. 
 
FOLATE METABOLISM 
 Folic acid (also known as folate, vitamin M, pteroyl-L-glutamic acid, 
and pteroylmonoglutamic acid)63 is forms of the water-soluble vitamin B9. Folic acid 
is itself not biologically active, but its biological importance is due 
to tetrahydrofolate and other derivatives after its conversion to dihydrofolic acid in 
the liver. 
 Vitamin B9 (folic acid and folate) is essential to numerous bodily functions. 
The human body needs folate to synthesize DNA, repair DNA, and methylate DNA as 
well as to act as a cofactor in certain biological reactions. It is especially important in 
aiding rapid cell division and growth, such as in infancy and 
pregnancy. Children and adults both require folic acid to produce healthy red blood 
cells and prevent anemia.  
 Most foods contain some folate. The highest concentrations are found in liver, 
yeast, spinach, other greens and nuts. The daily requirement is 100 ug and so stores 
are stores are sufficient only for 3 to 4 months in normal adults. 
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Folates act as coenzymes in the transfer of single carbon units – 
 
 
Figure 17: Biochemical functions of folate64 
 
 
 
 
 
 30 
 
HAEMATOLOGICAL ABNORMALITIES IN CHRONIC LIVER 
DISEASE 
 Liver disease causes a large number of changes in the blood than does disease 
in any other organ, except the bone marrow. It serves as a primary hematopoietic 
organ in utero and in adult life resumes its post of haematopoiesis in certain 
pathological states. 
BLOOD VOLUME  
 Plasma volume65 is increased in patients with cirrhosis, especially with long 
standing moderate to severe ascites. The hypervolemia may partially, and sometimes 
totally account for a low peripheral haemoglobin or erythrocyte level. Total 
circulating haemoglobin is reduced in only about half of the patients. 
ANEMIA IN CHRONIC LIVER DISEASE 
 Anemia occurs in up to 75% of patients with CLD66. The type, severity of 
anemia often varies depending on the duration & severity of cirrhosis, presence of 
complications and possibly the underlying aetiology in many cases. Majority of the 
cases are either a normochromic normocytic or macrocytic anemia; if associated with 
haemorrhage then it may be macrocytic. 
Multiple mechanisms67 operate in producing anemia – 
• Haemodilution – the plasma volume is frequently increased in patients with 
cirrhosis, especially with longstanding ascites; this may partly and or even 
fully account for the low haemoglobin in cirrhosis. 
• An important cause of anemia in chronic liver disease is bleeding, especially 
into the gastrointestinal tract. It may be acute or more often overt chronic 
bleeding, eventually producing an iron deficiency anemia. The presence of 
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coagulopathy often enhances the bleeding tendency further contributing to 
blood loss. 
• Nutritional factors play a major role in anemia, patients often being folate 
deficient. Alcoholics show more nutritional deficiencies than compared to 
other groups. 
• Portal hypertension, splenic sequestration of RBC as a part of hypersplenism. 
• The bone marrow response to anemia is reduced as part of chronic disease & 
increased levels of inflammatory cytokines.  
• Other rare causes include aplastic anemia that has been described in Non-A to 
E hepatitis. 
• Sideroblastic anemia that may occur in alcoholics and in hemochromatosis. 
• Reduced red cell survival due to multiple mechanisms 
• Alcohol is implicated in the pathogenesis of chronic liver disease and 
contributes to anemia by its direct effects on the liver and by other 
mechanisms. Eg –direct toxic effects on the erythrocytic precursors in the 
marrow, folate deficiency etc. 
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Figure 18: Alcohol and anemia 
 
 Iron overload is found to be higher among those who consume more than two 
alcoholic drinks per day compared to those who don’t drink. Cases of sideroblastic 
anemia complicating alcoholic liver disease have been reported. Alcoholics tend to be 
more deficient in folate due to the antifolate actions of alcohol. 
RBC SURVIVAL & HAEMOLYTIC ANEMIA68 
 Increased red cell destruction is almost constant in chronic liver disease and 
liver cell failure. Subiyah and Al-Hindawi using radiolabelled red cells were able to 
show decreased red cell survival that co-related well with splenomegaly and portal 
hypertension. The mechanisms are multifactorial - 
 The major factor is hypersplenism with destruction of red cells in the spleen. 
Spur cells commonly found in chronic liver disease have membrane defects, 
particularly decreased fluidity and this with altered architecture exacerbates splenic 
destruction. Coombs negative hemolytic anemia may occur in Wilson’s disease due to 
the toxic effects of free copper on RBC membrane. Rarely a Coombs positive 
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hemolytic anemia is seen chronic hepatitis, primary biliary cirrhosis & primary 
sclerosing cholangitis.  
 A rare syndrome of haemolysis with hyperlipidemia and acanthocytes has 
been described in patients with chronic alcoholic liver disease (Zieves syndrome). 
Instability of Pyruvate Kinase enzyme in alcoholic chronic liver disease contributes to 
haemolysis.  
 
Table 6: ANEMIA IN DCLD69 
   
 
   
   
   
  
 
 
 
 
 
 
 
 
 
 
 
ANEMIA IN CHRONIC LIVER DISEASE 
 
Anemia of chronic disease 
Folate deficiency 
Iron deficiency (blood loss) 
Aplastic anaemia (viral hepatitis, rare) 
Sideroblastic (alcohol) 
Hypersplenism 
Microangiopathy/disseminated intravascular coagulation  
 (DIC) (Rare) 
Autoimmune (rare) 
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LIVER DISEASE & HEMATINIC METABOLISM 
IRON METABOLISM 
 Iron status is largely influenced by the severity of chronic liver disease, 
complications like upper GI bleed and the use of alcohol. 
 In uncomplicated cirrhosis the usual pattern is a low normal serum iron levels 
with normal Total iron binding capacity. TIBC is a function of the amount Transferrin 
available in he blood. Transferrin is a Beta Globulin synthesized by the liver and 
hence in advanced liver disease where synthetic capacity is reduced, transferrin levels 
& hence TIBC is reduced.  
 Hepatic inflammation and necrosis tends to increase Ferritin levels both due to 
loss of storage capacity as well as an acute phase response. Large amounts of pro- 
inflammatory cytokines are produced, especially IL-6 that up regulates Hepcidin 
levels in the intestine and other cells. Hepcidin down regulates Ferroportin and 
reduced iron absorption from the intestines, hence producing a combination of high 
serum Ferritin levels coupled with low serum Iron and low normal Transferrin levels. 
This exemplifies the anemia of chronic disease, the most common type of anemia in 
chronic liver disease. 
 Patients who present with chronic upper GI bleed often develop Iron 
deficiency anemia characterized by low Ferritin, low serum iron and increased TIBC 
due to elevated Transferrin levels. However chronic liver disease acts as a 
confounding factor in terms of Ferritin levels and Transferrin levels; moreover the 
rise in MCV, which accompanies CLD and alcohol ingestion, may mask iron 
deficiency.  All proliferating cells express membrane transferrin receptors70 to acquire 
iron; a small amount of this receptor is shed into blood, where it can be detected in 
free soluble form. At times of poor iron stores, cells up-regulate transferrin receptor 
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expression and the levels of soluble transferrin receptor increase. This can be used to 
distinguish storage iron depletion in the presence of acute phase response or liver 
disease when a raised level indicates iron deficiency.  
 Alcoholic liver disease (ALD) is associated with iron overload71. The exact 
mechanism is not known but 2 theories have been proposed – alcohol induces 
expression of transferrin receptor 1 in intestinal cells thereby enhancing iron 
absorption and also down-regulates hepcidin thereby up-regulating ferriportin and 
enhancing iron absorption. 
 
VITAMIN B12 & FOLATE METABOLISM72 
 The liver stores folic acid & converts it to its active storage form 
tetrahydrofolate. Chronic liver disease is usually accompanied by folate deficiency 
especially alcoholic liver disease. This is largely due to dietary deficiency. Serum 
folate levels are almost always low. 
 The liver stores about 2 to 4 mg of Vitamin B12. Hepatic levels are reduced in 
liver disease. When hepatocytes become necrotic the vitamin is released into the 
blood and high serum B12 levels are recorded.  
 Altered B12 and folate metabolism causes macrocytosis. 
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CHANGES IN RED CELL SHAPE 
 Wide variety of changes in the red cell shape73 may be seen.  
1. MACROCYTES  
 Macrocytosis is commonly seen chronic liver disease per se & especially 
pronounced in alcoholic liver disease. The increase in MCV is due to: 
 - there is loading of the RBC membrane with cholesterol & lecithin due to the 
inhibition of Lecithin Cholesterol Acyl Transferase by the accumulating bile acids.  
- Deficiency of folic acid & abnormalities of B12 metabolism  
- Reticulocytosis associated with haemolysis and haemorrhage  
- Intrinsic abnormalities of bone marrow function  
2. MICROCYTIC HYPOCHROMIC CELLS  
 Red cells are often microcytic hypochromic due to chronic gastrointestinal 
bleeding, leading to iron deficiency. In portal hypertension, anaemia follows gastro-
esophageal bleeding and is enhanced by thrombocytopenia & disturbed blood 
coagulation. These patients also have increased incidence of acid peptic disease & 
ulcer bleed that contributes to bleeding. 
3. NORMOCYTIC CELLS  
 This is a combination of macrocytosis of chronic blood loss and the 
macrocytosis inherent with chronic liver disease.  
4. TARGET CELLS  
 They are also called thin macrocytes, found in both hepatocellular & 
cholestatic jaundice.  Alcoholics show genuine thick macrocytes related to the toxic 
effect of alcohol on the bone marrow. 
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5. SPUR CELLS / ACANTHOCYTES 
 They are cells with unusual thorny projections. Usually associated with far 
advanced liver disease especially alcoholic liver disease. Their appearance is a bad 
prognostic sign. 
 Bone marrow of chronic hepatocellular failure is hyperplastic and 
normoblastic. In spite of this, erythrocyte volume is depressed and the marrow 
therefore does not seem able to compensate completely for the anaemia  (Relative 
Bone Marrow Failure) 
Table 7: ABNORMALITIES OF RBC SHAPE IN CLD74: COURTESY OXFORD 
TEXTBOOK OF HEPATOLOGY 
 
ABNORMALITY PRIMARY LIVER DISEASE 
DISEASE IN OTHER 
SYSTEMS 
MACROCYTES MANY LIVER DISEASES 
MEGALOBLASTIC 
ANEMIA 
HYPOTHYROIDISM 
CYTOTOXIC DRUGS 
TARGET CELLS MANY LIVER DISEASES 
THALASSAEMIA 
HYPOSPLENISM 
OTHER 
HAEMAGLOBINOPATHIES 
SPHEROCYTES ZIEVES SYNDROME 
HEREDITARY 
SPHEROCYTOSIS 
AUTOIMMUNE 
HEMOLYSIS 
BURNS 
ACANTHOCYTES SEVERE CHRONIC LIVER DISEASE ABETALIPOPROTENEMIA 
SCHISTOCYTES HEPATORENAL SYNDROME 
DIC, TTP, HUS, HITT 
SYNDROME, 
MALIGNANT 
HYPERTENSION 
STOMATOCYTES ALCOHOLIC CIRRHOSIS 
HEREDITARY 
STOMATOCYTOSIS 
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WBC CHANGES IN CHRONIC LIVER DISEASE 
 WBC abnormalities in chronic liver disease may be due to underlying disease 
or complications like infection. Leucocytosis can occur in response to infection, 
haemorrhage, alcoholic hepatitis, cholangitis, hepatic abscess and malignancy. 
 Leucopenia is usually in the order of 1.5 – 3.0 * 109 cells with predominant 
depression of polymorphs. It may be due to hypersplenism, toxic effects of alcohol on 
the marrow or even ineffective haematopoiesis accompanying folate deficiency. Very 
little is known about the role of granulocyte colony-stimulating factor (G-CSF) or 
granulocyte macrophage colony-stimulating factor (GM-CSF) in leucopenia 
associated with cirrhosis75. Gurakar et al have shown that GM-CSF treatment for 
seven days in patients with cirrhosis and leucopenia resulted in an increase in the 
WBC count. Moreover, they showed no increase in the fraction of trapped leukocytes 
in the spleen. 
 Neutrophil function is also affected. A study by Altin et al demonstrated 
abnormal Neutrophil adhesion and chemotaxis in patients with decompensated 
chronic liver disease. There are low levels of serum complement C3. 
 Hypergammaglobulinemia is almost universal in chronic liver disease. It is 
due to immunization of the antigen presenting cells with enteric microbes and 
antigens that bypasses the filtering function of the liver via portosystemic shunts. IgA 
is markedly elevated in alcoholic cirrhosis whereas IgG is markedly elevated 
autoimmune hepatitis. 
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PLATELET ABNORMALITIES IN CHRONIC LIVER DISEASE 
 Abnormalities in platelet count and function are common in patients with all 
forms of liver disease.  
PLATELET COUNT 
 The thrombocytopenia of chronic liver disease76 (60 to 90 * 109) is very 
common due to multiple factors.  
- Splenic sequestration 
- Low levels of Thrombopoietin   
- Reduced half-life possibly related to auto-antibodies 
- Hypersplenism  
- Folate deficiency 
- Alcohol induced bone marrow suppression 
- Low grade DIC 
PLATELET FUNCTION 
 There is growing evidence of impaired platelet function in chronic liver 
disease. In particular aggregation77 is impaired in patients with advanced cirrhosis. 
This may be due to - 
- There is reduced availability of arachidonic acid for the synthesis for prostaglandins 
and also a reduction in platelet ATP and 5 HT.  
- Cross incubation studies suggest the possibility of a circulating factor that inhibits 
platelet aggregation 
- HDL isolated from patients with cirrhosis inhibited ADP induced platelet 
aggregation.  
- It is also reported that basal cytosolic content of calcium in platelets from cirrhosis 
was lower than of control. 
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- Even though VWB factor levels were relatively high in patients with cirrhosis, 
platelet-binding domains were defective contributing to defective adhesion. 
- High levels of platelet immunoglobulin’s were detected particularly in primary 
biliary cirrhosis, alcoholic cirrhosis and chronic active hepatitis.    
 The measurement of bleeding time assess the contribution of platelet number 
and function to primary haemostasis but does not have a close relationship to bleeding 
time, contrary to that found in patients with bone marrow diseases like leukaemia. 
 
HAEMOSTASIS IN CHRONIC LIVER DISEASE 
 The liver plays a central role in haemostasis and thrombosis. Liver 
parenchymal cells are the site of synthesis of most coagulation factors, the 
physiologic inhibitors of coagulation- protein C, protein S, and Antithrombin, and 
essential components of the fibrinolytic system- plasminogen, Alpha2-antiplasmin, 
and thrombin activatable fibrinolysis inhibitor (TAFI)78.  
 The liver also regulates haemostasis and fibrinolysis by clearing activated 
coagulation factors and enzyme-inhibitor complexes from the circulation. Therefore, 
when liver dysfunction occurs in patients with liver disease, a complicated 
haemostatic derangement ensues, which can lead to bleeding, thrombosis, or neither 
bleeding nor thrombosis. 
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Table 8: Effects of liver disease on haemostasis79 
HAEMOSTASIS IN LIVER DISEASE 
1. Reduced synthesis of clotting factors 
-Hepatic dysfunction per se 
- Vitamin K deficiency  
2. Reduced synthesis of endogenous anticoagulants 
3. Production of abnormal dysfunctional proteins 
4. Enhanced Fibrinolytic activity 
- Reduced clearance of activators of Fibrinolysis 
- Reduced production of inhibitors of fibrinolysis 
5. Reduced Hepatic clearance of activated clotting factors 
6. Disseminated Intravascular Coagulation 
7. Platelet abnormalities 
 
REDUCED SYNTHESIS OF CLOTTING FACTORS 
 The liver is the site of synthesis of most procoagulant proteins. As a result, 
decreased levels of coagulation factors V, VII, IX, X, and XI and prothrombin are 
commonly observed in patients with liver failure.80 In contrast, factor VIII levels are 
increased which may be related to the elevated level of its carrier protein VWF and to 
decreased clearance of factor VIII from the circulation by the liver low-density 
lipoprotein-related receptor.81 Factor VIII is synthesized primarily in hepatic 
sinusoidal endothelial cells, whose function is preserved in liver disease. Qualitative 
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defects in clotting factors can arise as a consequence of hepatic failure. Because of 
vitamin K deficiency or decreased production of gamma glutamic carboxylase, a 
proportion of circulating vitamin K dependent coagulation factors II, VII, IX, and X 
may be deficient in -carboxylated glutamic acid residues giving rise to impaired 
function of these factors. 
REDUCED SYNTHESIS OF ENDOGENOUS ANTICOAGULANTS 
 Levels of anticoagulant protein C, protein S, anti-thrombin, heparin cofactor 
II, and Alpha2-macroglobulin are decreased in patients with liver disease. Because 
tissue factor pathway inhibitor (TFPI) is mainly synthesized by endothelial cells, 
normal levels of this protein are present in patients with hepatic failure. 
PRODUCTION OF DYSFUNCTIONAL PROTEINS 
DYSFIBRINOGENEMIA 
 Fibrinogen levels are in the normal range in patients with chronic liver 
disease, but may be decreased in patients with decompensated cirrhosis. The 
dysfibrinogen is characterized by an increased content of sialic acid,82 possibly caused 
by enhanced levels of glycosyltransferases in hepatocytes. Hypersialization of 
fibrinogen impairs its polymerization but does not affect the interaction of fibrinogen 
with platelets. 
 Dysfibrinogenemia accounts for the prolonged thrombin time in patients with 
chronic liver disease. This should be suspected when aPTT is prolonged with normal 
fibrinogen levels and fibrinogen degradation products within the normal range.  
Von Willi Brand Factor 
 Profoundly elevated levels of von Willebrand factor (VWF) antigen are 
frequently observed in patients with liver disease and were suggested to result from 
endothelial damage possibly mediated by bacterial infection. The high levels of VWF 
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may ameliorate the hemostatic defect caused by thrombocytopenia and platelet 
function defects.83 In patients with liver disease the regulation of VWF multimer size 
and activity can be impaired because of reduced synthesis of VWF-cleaving protease 
ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type 1 
repeats) by stellate cells in the liver.18 However, a reduced multimer size of VWF was 
found in patients with liver disease, suggesting that other proteases, such as plasmin, 
elastase, and granzyme B, contribute to VWF proteolysis. 
ENHANCED FIBRINOLYTIC ACTIVITY 
 There is evidence for enhanced fibrinolytic activity in patients with liver 
disease. Hepatocytes synthesize plasmin inhibitors such as Alpha2 anti-plasmin as 
well as tissue plasminogen activator inhibitor (PAI). 
 In patients with cirrhosis PAI is reduced even without features of clotting 
activation. The clearance of Tissue plasminogen activator by the hepatocytes is 
decreased.  The resultant increase in the ratio of plasminogen activator to its inhibitor 
is thought to lead to enhanced fibrinolysis.Ascitic fluid contains plasminogen 
activators as well as fibrin degradation products indicating active intraperitoneal 
coagulation.  This accounts for the increased bleeding tendency following LeVeen 
shunt.  
DISSEMINATED INTRAVASCULAR COAGULATION 
 The release of tissue thromboplastin like material by necrotic liver coupled 
with low-grade endotoxemia & reduced clearance of activated clotting factors 
contributes to the triggering of DIC in patients with severe chronic liver disease.  
Whatever the background state, cirrhotic patients are at a greater risk of DIC 
particularly when complicated by sepsis and hypotension. 
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CONCEPT OF REBALANCED HAEMOSTATIC SYSTEM 
 Because both procoagulant and anticoagulant proteins decline in patients with 
liver diseases, it appears that the hemostatic system is rebalanced. This may explain 
why most patients with liver disease usually do not exhibit severe bleeding 
manifestations during invasive procedures, and why patients are not protected against 
thrombosis.This balance is quite delicate and vulnerable to be tipped toward bleeding 
or thrombosis depending on the particular trigger that is inflicted. 
IMPAIRED HAEMOSTASIS CHANGES THAT PROMOTE 
HAEMOSTASIS 
Thrombocytopenia Elevated levels of VWF 
 
Platelet function defects Decreased levels of ADAMTS-13 
Low levels of factors II, V, VII, IX, X, 
and XI 
Elevated levels of factor VIII 
 Vitamin K deficiency Decreased levels of protein C, protein S, 
antithrombin, alpha2-macroglobulin, and 
heparin cofactor II 
 
Dysfibrinogenemia  
Elevated t-PA levels Low levels of plasminogen 
Low levels of 2-antiplasmin, factor XIII, 
and TAFI 
 
 
Table 9: REBALANCED HEMOSTATIC SYSTEM84 
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DESIGN OF THE STUDY 
MATERIALS AND METHODS 
 
 To assess the hematological abnormalities in decompensated chronic liver 
disease, a cross sectional analytical study was conducted in Tirunelveli Medical 
College hospital from June 2011 to September 2012.  
 50 patients admitted to the General Medical and Intensive Medical care unit 
with clinical features suggestive of decompensated chronic liver disease were taken 
up for the study.  
 Patients suffering from acute liver cell failure, known GI malignancy or 
known primary hepatocellular carcinoma, primary coagulation disorders , liver cell 
failure due to infective causes, from end stage medical diseases like COPD, Coronary 
artery disease, cardiac  failure, CKD were excluded from the study. 
 All patients taken up for the study were evaluated in detail. Oral consent was 
obtained for clinical examination and lab investigations. Written consent was obtained 
for procedures such paracentesis, Upper GI endoscopy and viral marker studies. 
Following points were noted in history 
• Fatigue and weight loss 
• Anorexia and flatulent dyspepsia 
• Abdominal pain 
• Jaundice, itching, colour of urine and feces 
• Swelling of legs and abdomen 
• Haemorrhage – haemetemsis, malaena, nose, gums, skin 
• Loss of libido; menstrual history 
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• Urine output 
• Past history : jaundice, hepatitis, drugs ingested, blood transfusions, diabetes, 
hypertension, tuberculosis, coronary artery disease, trauma, surgeries, needle 
prick injuries 
• Personal history – Alcoholism, smoking, high risk behaviour 
• Family history – liver disease, autoimmune disease 
A detailed clinical examination was done in  all cases 
• Nutrition, fever, fetor hepaticus, jaundice, pigmentation, purpura, 
clubbing, white nails, vascular spiders, palmar erythema, gynecomastia, 
testicular atrophy, distribution of body hair, parotid enlargement , 
dupytrens contractures, vital signs. 
• Abdomen – ascites, abdominal wall veins, liver , spleen , bruits 
• Neurological changes – mental functions, flapping tremor and 
constructional apraxia 
 Patients were submitted to a number of blood investigations; samples obtained 
were personally handed over to the  lab and results were obtained in person. Blood 
samples were anticoagulated when needed with EDTA. 
 Clinical examination and basic investigations help in establishing a diagnosis 
of chronic liver disease. According to Schiff Hepatology 11th edition chapter 1 page 3 
line 3 -  The presence of two physical findings (ascites and evidence of portosystemic 
encephalopathy (asterixis) and two laboratory findings (hypoalbuminemia (<2.8 g/dL) 
and a prolonged prothrombin time (international normalized ratio >1.6) indicates a 
diagnosis of cirrhosis of the liver. 
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 Clinical findings are supported by USG evidence of cirrhosis, which can 
detect 95 % of cirrhosis (Schalm Sw. The diagnosis of cirrhosis J.Hepatol 1997; 
27:1118) 
 After establishing the diagnosis, patients were evaluated for hematological 
abnormalities. All investigations were done at the clinical pathology lab at Tirunelveli 
Medical college hospital except Iron studies, folate, B12 and fibrinogen levels which 
were done at an outside lab due to unavailability at the medical college laboratory.   
 
RBC abnormalities  
1.   RBC Count – RBC count are done in Neubauers chamber using Hayems fluid 
 or  autoanalyser. 
 Normal value – 4.5 to 6 million per mm3 
2.  Hemoglobin estimation -  done by Sahlis method, based on conversion of 
 hemoglobin to acid hematin or auto analyzer.  
 Normal value – Male – 14 to 18 gm %, females – 12 to 16 g % 
3.  Packed cell volume (PCV): It is done in autoanalyser or using 
 microhematocrit capillary method.  
 Normal value : Male 42 to 52%. Female: 37 to 47 % 
4.  MCV, MCHC, MCH: 
 - are estimated by autoanalyser  
 MCV - 80 to 97 fl 
 MCH - 26 to 33 pg/dl 
 MCHC - 32-35 gm/dl. 
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5. Peripheral smear for blood picture 
 Using stains, blood picture is examined with a standard lab microscope. 
Low power field examination: 
 Quality of film 
 Number, distribution and staining of WBCs  
 RBCs examination 
High power field examination:  
 Assess RBC – Size, Shape,Hemoglobin concentration  
Oil immersion examination: 
 Assess atypical cells and inclusion bodies  
6. Reticulocyte count: 
 Stain - 1% brilliant cresyl blue 
 Normal - 0.2-2% 
To assess WBC abnormality: 
1.  Total WBC count: Done by QBC method or using Neubauer's chamber with 
 Turke's fluid  
 Normal 3,800-9,000 cells per mm3 
2.  Differential count:  Assessed by QBC method or direct staining and 
 visualizing with lab microscope. 
To Assess hemostasis 
1.   Platelet count : estimated by autoanalyser, if found to be low, collaborated 
  with  peripheral  smear;  if  discrepancy  between  platelet  count  and 
  peripheral smear then a manual count was done manually by Rees‐Eecker 
  method i.e with staining with brilliant cresyl blue dye. 
2.  Prothrombin time: Normal 10-14 sec.  
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3.  Activated partial thromboplastin time: Normal 24-34 sec. 
4.  Fibrinogen levels 
Reference range – 150 to 400 mg/dL 
Iron Studies  (chemiluminescent method) 
• Serum iron (50 to 170ug/dL) 
• Ferritin levels (10 to 291 ng/ml) 
• Iron binding capacity (250 to 450 ug/dL) 
• Transferrin (176 to 280 ug/dL) 
•  Transferrin saturation (20 to 50%) 
Folate levels (> 5.38 ng/ml) (chemiluminescent method) 
B12 levels (118 to 800 pg/ml) (chemiluminescent method) 
Upper GI endoscopy 
 UGI endoscopy was done at medical gastroenterology department. After 
obtaining the patient's written informed consent, Patients were kept on over night nil 
oral and upper GI endoscopy was done. Results were collected in person and were 
correlated with other findings to establish the diagnosis. 
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INCLUSION CRITERIA 
 
1.  All patients with liver disease whose symptoms and signs persists for more than 6 
months 
2.  Alcoholic cirrhosis, post-necrotic cirrhosis, metabolic causes of liver diseases were 
taken up for the study 
 
EXCLUSION CRITERIA 
1. Patients with underlying malignancy or known primary hepatocellular carcinoma 
were excluded 
2. Patients with primary coagulation disorder or primary abnormalities of haemostatic 
function were excluded. 
3. Acute hepatic failure was excluded 
4.Patients with preexisting anemia due to other causes were excluded. 
5. Patients suffering from end stage medical diseases like COPD, Coronary artery 
disease, cardiac failure, CKD were excluded 
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6 patients had Hepatitis B and 1 had Hepatitis C; all these 7 patients had cirrhosis.  
Autoimmune hepatitis and cirrhosis were present in 2 females and 1 male patient. 
PAST HISTORY OF JAUNDICE 
 Of the 50 patients with DCLD only 14 patients gave past history of jaundice. 
Serology proved that 4 patients had hepatitis B and 1 had hepatitis C. One female 
patient had recurrent history of jaundice and was diagnosed as a case of Wilsons 
disease. 
SERUM PROTEINS 
 Since one of the major functions of the liver is to synthesize proteins, the total 
proteins and albumin to globulin ratio was assessed in this study. 
Table 12: TOTAL PROTEIN LEVELS 
 
 Among 50 patients only 16 % of patients had a total protein level between 6 to 
7 g/dL. The rest 84 % had a total protein less than 6 g/dL; majority (60%) falling 
between 5 to 6 g/dL. 4 patients had a total protein below 4 g/dL. These 4 patients had 
severe liver disease with an average CPS score of 13; hence reflecting the poor 
synthetic function of the liver.  
Total protein (A + G) Number of Patients % 
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Comparing alcoholic and non-alcoholic patients with upper GI Bleed reveals that 
alcoholic patients with an upper GI bleed have stastically significantly lower values of 
Hb, PCV and RBC count compared to the latter. (P value -<0.05) 
 Like wise comparing alcoholic and non-alcoholic patients without any GI 
bleed also shows stastically significantly lower values among the alcoholic group. (P 
value –<0.05 
CHARACTERISTICS OF THE ANEMIA 
 The most common type of blood picture was normocytic red cells seen in 22 
patients, of which 5 patients had a normal Hb value. Macrocytic picture was observed 
in 15 patients. Of these 14 patients had alcoholic liver disease and the etiology was 
undetermined in the other. 11 patients had a microcytic blood picture of which 8 
patients had an upper GI bleed and the one patient with hemochromatosis had 
sideroblastic anemia that was proved with bone marrow and iron studies. Dimorphic 
blood picture was seen in 2 patients.  
 
Table 20: CHARACTERISTICS & MORPHOLOGY OF ANEMIA 
Peripheral smear Number Average MCV 
Macrocytic 15 101.8 
Normocytic 22 89.9 
Microcytic 11 71.39 
Dimorphic 2 78 
 
 Target cells were seen only in 3 patients and acanthocytes in 2 patients, these 
patients had severe disease with an average CPS of 13. One female patient with 
Wilsons disease was noted to have few spherocytes in the peripheral smear. All 
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WBC ABNORMALITIES 
 
 The analysis of WBC was done with total and differential counts. Counts 
ranged from 2700 to 20800.  
Table 27: WBC COUNT IN DCLD 
 
 
 
 
 
 
 
 
 Among the 50 patients Leucocytosis was observed in 8 patients, 4 patients 
with a count above 15000 had SBP. The other 4 had low-grade fever probably as a 
result of endotoxemia. Leucopenia was observed in 13 patients. Eosinophilia was 
observed in 5 cases, neutrophilia in 8 patients. 
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COAGULATION PROFILE 
 
 The liver secretes all clotting factors except VIII & VWBf. Coagulation 
profile was assessed using aPTT, PT-INR and fibrinogen levels. 36 patients had a 
prolonged INR and 6 patients among this group had prolonged APTT. 3 of these 
patients proved to have DIC with elevated D-dimer and low fibrinogen levels, the 
other 3 patients probably had dysfibrinogenemia, which is suspected when aPTT is 
prolonged in the presence of normal fibrinogen levels. Among the 13 patients with 
upper GI bleed 9 had prolonged INR; indicating other factors play a role in GI bleed. 
Fibrinogen levels were reduced only in 9 out of 50 patients of whom 3 had DIC. 
 
 
Table 30: INR VALUES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INR Number 
1.3 to 1.6 17 
1.7 to 2 10 
2 to 2.5 7 
>2.5 2 
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DISCUSSION 
 This study conducted at Tirunelveli Medical College hospital involving 50 
patients has thrown light on many of the hematological abnormalities that is seen in 
decompensated chronic liver disease.  
 
RBC ABNORMALITIES 
 
 According to an article –“ Spectrum of anemia associa ted with chronic 
liver disease by Rosario Gonzalez-Casas, E Anthony Jones, and Ricardo Moreno-
Otero” published in the World Journal of Gastroenterology in 2009; anemia of diverse 
etiology occurs in up to 75 to 80 % of cases of chronic liver disease.   The 
mechanisms operating to produce anemia include the following -  
- Haemodilution 
- Portal hypertension and splenic sequestration of red cells 
- Bleeding into the gastrointestinal tract from varices or bleeding peptic ulcers 
- Nutritional deficiencies of folate, B12 and iron 
- Suboptimal bone marrow response to chronic inflammation 
- Reduced red cell survival  
- Alcohol through diverse mechanisms. 
- Reduced erythropoietin levels  
 In our study 90 % of the patients were anaemic; this value is significantly 
higher compared to the previously cited article. 76 % of the patients had a moderate 
degree of anemia whereas 14 % of the patients had severe anemia below 6 g/dL. 
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 The changes in Hb, RBC count and Hct parallels each other. The reason for 
the more severe degree of anemia in this study population of 50 patients could be the 
following: 
-  52 % of patients of this study population had alcoholic liver disease.   *Alcohol’s 
adverse effects on the hematopoietic system are both direct and indirect. The direct 
consequences of excessive alcohol consumption include toxic effects on the bone 
marrow. Alcohol’s indirect effects include nutritional deficiencies that impair the 
production and function of various blood cells.  
 In this study the average Hb of patients with alcoholic liver disease was 8.7 
g/dL compared to 9.3 g/dL of patients with other causes of DCLD. This clearly shows 
alcoholism by itself contributes significantly to the causation & burden of anemia.  
- This study was undertaken in a Government medical college hospital where all 
patients belonged to the lower strata of the socio-economic circle; hence they 
probably had pre existing nutritional deficiencies that added on to burden of chronic 
liver disease. 
 Another interesting observation from this study was that males had a higher 
degree of anemia compared to females. The average Hb of males was 8.9 g/dL 
compared to 9.1g/dL in females. The reasons probably are 
- Males had a more severe liver disease compared to females. The Average CPS of 
males was 11.2 compared to 8.1 for females 
- 11 males had an upper GI bleed compared to only 2 females. In this study the 
average Hb of patients with an upper GI bleed was 6.5 g/dL compared to 9.8 g/dL 
with those without a bleed.  
- 60 % of the males had alcoholic liver disease compared to no alcoholic liver disease 
in females. 
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TYPE OF ANAEMIA 
 Several studies have been published describing the morphology and frequency 
of the types of anemia in chronic liver disease; the type of anemia varying in 
frequency in different studies.   
 According to Sherlock’s textbook of the liver & Oxford textbook of medicine 
the most common type of anemia is a normochromic normocytic anemia. A Chapter 
by Atul B Mehta & A Victor Hoffbrand in the postgraduate hematology, fifth edition 
mentions that 66 % of patients show a macrocytic picture, a view that is shared by 
Garnet Cheney – “Morphology of the erythrocytes in cirrhosis” published in the 
California & Western medicine journal 1967. A study by Mishra et al in 1982 said 
that the most common type of anemia is a normochromic normocytic anemia seen in 
79% of the patients.  
 An article published by Eric William Camille et al in The Journal of French 
studies & research (volume 17, Number 2, 87-91, April-May-June 2007) elucidates 
that 43.3 % of patients had a normochromic normocytic anemia where as 20 % had a 
microcytic hypochromic anemia. 
 Our particular study conforms more closely to the French study; 44% of the 
patients had a normochromic normocytic anemia, 30 % had a macrocytic blood 
picture and 22 had microcytic hypochromic anemia. 16 % of the patients with a 
microcytic blood picture had an upper GI bleed and one patient with 
hemochromatosis had sideroblastic anemia that was proven with iron studies and bone 
marrow. 
 Various abnormal types of red cells have been described in cirrhosis.  
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Target cells are bell-shaped RBC that assumes a target shape on dried films of blood. 
Cooper RA, Arner EC, Wiley JS et al explained that target cells form due to loading 
of the red cell membrane with cholesterol and lecithin resulting from diminished 
lecithin cholestrol acyl transferase activity (LCAT). Bile acids are believed to inhibit 
LCAT activity. 
 Spur cells or acanthocytes are seen in severe liver disase. They are cells with 
unusual irregularly placed thorny projections & are believed to be formed from 
echinocytes or burr cells due to the interaction of abnormal HDL found in liver 
disease with the red cell membrane (Owen JS, Brown DJ, Harry DS et al – 
“Erythrocyte Echinocyte in liver disease.” Role of abnormal plasma HDL-J Clini. 
Invst. 1985)   
 In our study only 3 patients showed target cells and 2 showed acanthocytes. 
One female patient with Wilsons disease showed few spherocytes suggesting Copper 
mediated non-immune haemolysis. 
 
IRON STUDIES 
 Serum iron parameters are affected by liver disorders.  
 Ferritin is the major iron storage protein in the body. Hepatic parenchymal 
cells contain appreciable amounts of ferritin, and it is known that liver disease can 
affect the serum ferritin levels regardless of any change in iron stores. An article 
published by Elizabeth et al in Ann Intern Med. 15 April 2003; 138(8):627-633 
showed correlation between ferritin levels and the degree of hepatic fibrosis. 
 An article published by A Jacobs and M Norwood in NEJM 1975 showed high 
ferritin concentrations were associated with severe or active hepatocellular disease. 
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In our study 28 % of patients had a normal level of ferritin with an average CPS of 
8.2.  40 % of the patients had ferritin levels between 292 & 900 ng/ml with an average 
CPS of 11.05; 16 % of the patients had ferritin levels above 900ng/ml with an average 
CPS of 13.5;This shows as the ferritin levels rises the severity of liver disease also 
increases indicating a positive correlation between elevated ferritin levels and liver 
cell damage. However, even patients with a low ferritin level had a higher CPS than 
patients with a normal level. This was explained by the fact that all these patients had 
experienced upper GI bleed and worsening CPS.  
 Transferrin is an iron binding glycoprotein synthesized by the liver that 
transports iron to various tissues. In our study the average CPS of patients with a 
normal transferrin was 8.4; as the transferrin levels decreased the severity of liver 
disease increased. This showed an inverse correlation between severity of liver 
disease and transferrin levels.  This conforms to the study published by Naciye 
Şemnur BÜYÜKAŞIK, Işılay NADİR et al in the Turkish journal of gastroenterology 
2011; 22 (6): 606-611– “serum iron parameters in cirrhosis” showed a good 
relationship between severity of parenchymal liver failure and aberrant serum iron test 
results. Patients with advanced cirrhosis frequently had decreased transferrin levels 
and elevated ferritin levels. 
 The overall interpretation of iron studies in relation to anemia should be done 
cautiously in patients with cirrhosis, as the liver disease itself alters iron parameters, 
depending on severity. In our study 66 % of patients had a profile showing anemia of 
chronic disease. 24 % of patients were iron deficient and 10 % had features of iron 
overload. In patients with iron deficiency ferritin levels were low; however this may 
be an underestimation of the actual number of cases of iron deficiency because ferritin 
being an acute phase reactant and being elevated in liver damage may mask iron 
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deficiency. Hence a better indicator of iron deficiency would be estimation of soluble 
free transferrin receptor levels in blood which is elevated in iron deficiency 
independent of liver disease, renal disease or inflammatory state.  
 4 patients with evidence of iron overload had alcoholic cirrhosis. Alcohol 
increases iron absorption through two possible mechanisms – increased uptake of iron 
into hepatocytes in a specific manner through the increased expression of transferrin 
receptor (TfR) 1; and increased intestinal iron absorption by the lowering of hepcidin 
(Dysregulation of systemic iron metabolism in alcoholic liver diseases. Kohgo Y, 
Ohtake T et al: J Gastroenterology Hepatol. 2008) 
 
FOLATE LEVELS 
 
 According to a study published by FREDERICK A. KLIPSTEIN and JOHN 
LINDENBAUM – “ folate deficiency in chronic liver disease”: Blood 1965 “ up to 72 
% of patients with chronic liver disease had suboptimal levels of folate in the blood. 
Alcoholic patients had more severe deficiency compared to other patients.  
 According to Kurt J. Isselbacher, M.D. and Norton J. Greenberger, M.D. N 
Engl J Med 1964; a number of mechanisms by which the phenomenon of folic acid 
deficiency might occur in the alcoholic patient and lead to macrocytic anemia. 
Decreased intake, impaired intestinal absorption or deranged hepatic metabolism of 
folic acid might all be involved. Alcohol was shown to inhibit Intestinal conjugase; an 
enzyme necessary for folate reduction and absorption from the gut. 
 In our study 96% of patients were folate deficient, 32% having mild 
deficiency and 64 % having moderate to severe deficiency. However only 30 % of 
patients had a macrocytic picture. The levels did not correlate with severity of liver 
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disease. It was stastically proven that patients with alcoholic liver disease had a much 
lower folic acid levels compared to other causes of CLD. 
 The average levels of folate in alcoholics were 2.3 ng/ml compared to 3.2 
ng/ml in nonalcoholic patients. 
 Hence our study more or less parallels these western studies but for the fact 
that a much higher proportion, 96 % of patients had suboptimal folate levels. This can 
again be accounted by the fact that 52 % of the study population had alcoholic 
cirrhosis and all patients were from the lower socioeconomic status, probably 
reflecting a pre-existing nutritional deficiency.  It is clear that folate deficiency is very 
common in cirrhosis patients but more extensive studies correlating bone marrow 
morphology with folate levels in cirrhotic patients are required before any conclusive 
results can be drawn regarding contribution of folate deficiency to degree and severity 
of anaemia in cirrhosis patients. 
 
VITAMIN B12 
 Several studies have established the fact that Vitamin B12 levels are elevated 
in patients with chronic liver disease with hepatocellular necrosis.  
The mechanisms that were initially postulated include - 
-Increased absorption of the vitamin from the gastrointestinal tract 
- Altered serum proteins that results in enhanced B12 binding. 
- Spurious elevations due to the presence of substances that cross-react with B12 
-The release of the vitamin from the liver as a result of hepatocellular damage and 
necrosis. 
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 A study conducted by Thomas D. Stevenson M.D and Marion F. Beard, M.D. 
– “Serum Vitamin B12 in liver disease” published in NEJM 1959 investigated the 
causes of elevated B12 levels in chronic liver disease. Their study using radioactive 
B12 conclusively showed normal absorption of B12 from the gut, normal serum 
binding capacity of B12 & normal excretion rates. They concluded by saying the most 
obvious explanation for the increased serum vitamin B12 content in the presence of 
liver disease is the release of the vitamin from the liver as the result of hepatocellular 
necrosis.  
 The principal evidence for this mechanism from their study is the observation 
that the serum content was increased only in the presence of hepatocellular disease, 
declining toward normal with evidence of improvement of hepatocellular function, 
and that other mechanisms seemed adequately excluded. 
 In our study 32% of patients had a normal vitamin B12 level with an average 
CPS of 7.7. 40 % had levels between 800 to 1600 pg/ml with an average CPS of 9.3 
& 28 % had levels above 1600 pg/ml with an average CPS of 12.  
 This clearly indicates that as the severity of liver disease increases the B12 
levels rise. This is in accordance to the previously published studies.  
 
WBC ABNORMALITIES 
 
 According to Sherlocks textbook of Hepatology, in cirrhosis there is usually a 
leucopenia in the order of 1500 to 3000 cells/dL. It may be more severe in which case  
-Hypersplenism 
-Alcohol & cytokine induced bone marrow suppression  
-Significant folate deficiency should be ruled out. 
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Studies by Rosenbloom, A.J. et al published in JAMA in 1995; elevated levels of IL-6 
in patients with cirrhosis suggested ongoing leucocyte activation, and  predicted the 
development of a systemic inflammatory response syndrome. 
 Altin et al have described abnormalities of Neutrophil function – adhesion and 
chemotaxis accompanied with low levels of C3 in DCLD. Very little is known about 
the role of granulocyte colony-stimulating factor (G-CSF) or granulocyte macrophage 
colony-stimulating factor (GM-CSF) in leucopenia associated with cirrhosis. Gurakar 
et al have shown that GM-CSF treatment for seven days in patients with cirrhosis and 
leucopenia resulted in an increase in the WBC count. 
 Hypergammaglobulinemia is almost universal in chronic liver disease. It is 
due to immunization of the antigen presenting cells with enteric microbes and 
antigens with resultant lymphocyte activation. IgA is elevated in alcoholic cirrhosis 
whereas IgG elevated in autoimmune hepatitis. 
 In our study group of 50 patients the WBC count ranged from 2700 to 20800. 
26% of patients had leucopenia with count less than 4000. 58% had normal count & 
16 % of patients had Leucocytosis. 4 patients with count above 15000 had proven 
spontaneous bacterial peritonitis; the other 4 had low-grade fever and severe liver 
disease probably resulting from endotoxemia.  
 Eosinophilia was observed in 5 cases probably resulting from underlying 
parasitic infection. 
 It was not possible to obtain functional studies of WBC nor electrophoretically 
determine the type of immunoglobulin’s elevated in cirrhosis due to lack of facilities. 
However all 50 patients had A:G reversal. It was due to both decreased synthesis of 
albumin with deteriorating liver function and increased synthesis of immunoglobulin. 
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 An interesting observation that was made was the correlation of A:G ratio 
with severity of liver disease. When the ratio was lower, the severity of liver disease 
was higher – 6% of patients had A:G ratio of <.05 with an average CPS of 13.6 
whereas when the A:G ratio was  0.8 to 0.9 the CPS was 8.3. 
 
PLATELET ABNORMALITIES 
 Several studies on platelet defects in DCLD have been done before. According 
to an interesting article by Jody L Kujovich MD – “Haemostatic defects in end stage 
liver disease “; Critical care clinics 21 (2005) - mild to moderate thrombocytopenia 
occurs in 49 to 64 % of patients with DCLD. The platelet count is rarely less than 30 
to 40 thousand. The etiology of thrombocytopenia is multifactorial –  
- Splenic sequestration of platelets 
- Low Thrombopoietin levels 
-Hypersplenism 
-Reduced platelet half-life related to autoantibodies 
- Folate deficiency 
- Alcohol induced bone marrow suppression 
- DIC 
- Sepsis 
- Drugs 
 Functional platelet defects are well described in several studies.  
 Escolar G et al reports that platelet aggregation seems to be particularly 
affected in as much as 46% of patients with DCLD.  
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 The possible mechanisms have been postulated by a study by Ballard HS, 
Marcus AJ et al - “Platelet aggregation in portal cirrhosis”; Arch Intern Med 1976. 
They include 
- Reduced availability of arachidonic acid for prostaglandin synthesis  
- Reduced platelet ATP and serotonin 
- Circulating factors that inhibits platelet aggregation - FDP and D- dimers, plasmin 
degradation of platelet receptors, dysfibrinogenemia, and excess nitric oxide 
synthesis.  
- Nitric oxide is a powerful vasodilator and inhibitor of platelet adhesion and 
aggregation produced by vascular endothelial cells. 
- HDL isolated from cirrhotic patients inhibit ADP induced platelet aggregation 
- Platelet binding domains are abnormal thus preventing efficient binding to Von 
Willi Brand factor during adhesion. 
 Comparison of various studies showed conflicting reports regarding bleeding 
time as a test to assess platelet function adequately. Blake JC  et al.” Bleeding time in 
patients with hepatic cirrhosis”. BMJ 1990 reports that bleeding time is prolonged in 
as much as 40% of patients with cirrhosis. However another study by Basili S et al. 
“Bleeding time does not predict gastrointestinal bleeding in patients with cirrhosis”; J 
Hepatol (1996) reports bleeding time as an inadequate and ineffective test for platelet 
function and correlates poorly with bleeding tendency.  
 In our particular study 50% of patients had thrombocytopenia (< 1 lakh) of 
which 80% had mild to moderate thrombocytopenia (50 to 100 thousand). This 
conforms to the article by Jody L Kujovich mentioned earlier.  The rest 20 % had 
severe thrombocytopenia (below 50000).  
 82 
 
 Our study also compared the degree of thrombocytopenia to the spleen size 
clinically palpable from the costal margin. The average spleen size of patients with 
count between 75 to 100 thousand was 4.6 cm, those with a count of 50 to 75 
thousand was 6cm and those with a count less than 50000 had an average spleen size 
of 7.7 cm. According to a study by Aster RH et al “Pooling of platelets in the spleen” 
J Clin Invest 1966 the normal spleen sequesters up-to 33% of the platelet mass 
exchanging freely with circulating platelets. Markedly enlarged spleens may sequester 
up-to 90 % of platelets. This report conforms closely with our study. 
 In our study, of the 13 patients who had an upper GI bleed, 3 patients had 
normal platelet counts and the rest had average platelet count of 92000. The bleeding 
time was prolonged only in 12% of patients with thrombocytopenia. This clearly 
indicates that bleeding time as an insensitive test for platelet function conforming to 
the result shared by Basili S et al; and functional abnormalities probably play a role. 
However due to lack of facilities platelet functional studies could not be taken up. 
 
COAGULATION ABNORMALITIES 
 A deranged coagulation system is very common in chronic liver disease.  
There is reduced synthesis of all coagulation factors (except factor VIII & Von Willi 
Brand factor), Vitamin K deficiency, Hyperfibrinolysis & dysfibrinogenemia, all 
contributing to increased bleeding tendency.  
 Tripodi et al HEPATOLOGY 2005 through an elegant study have shown in 
addition to the diminished hepatic synthesis of clotting factors, patients also have a 
profound deficit of natural anticoagulants, mainly of protein C (a protein synthesized 
by the liver), and also of anti-thrombin, which may counterbalance the bleeding 
tendency caused by the deficiency in procoagulants. This was the concept of the 
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Rebalanced Haemostatic system, which can be tipped in favor of bleeding or 
thrombosis depending on the clinical situation. 
 In our particular study as much as 72% of patients had a prolonged PT-INR 
and 6 patients within this group had a prolonged aPTT, though only 25 % of these 
patients had an upper GI bleed. This may suggest a rebalanced coagulation system in 
action to prevent bleed, however we did not have any patient with DCLD who 
presented with thrombosis. Individual assessment of procoagulants & endogenous 
anticoagulants were not possible due to lack of facilities and are definitely warranted 
for more conclusive results. 
 According to Bakker CM et al “Disseminated intravascular coagulation in 
liver cirrhosis” J Hepatol 1992 low grade DIC is a feature in upto 7 to 25 % of 
patients with cirrhosis particularly Child C cirrhosis.  In our study only 6% of patients 
were in DIC, all patients suffering from spontaneous bacterial peritonitis and sepsis.  
 Thus from this limited study of 50 patients with decompensated chronic liver 
disease we were able to draw many inferences regarding the haematological 
abnormalities that contribute to the morbidity of patients.  
 Many of the results obtained conform to previously done studies mentioned 
earlier but whether these results can be extrapolated to the larger population of 
cirrhotic patients as a whole is not definitely known and needs larger, more 
comprehensive studies with a wider range of patient selection. 
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CONCLUSIONS 
 Many conclusive results regarding the haematological abnormalities in 
decompensated chronic liver disease were obtained with this limited study involving 
50 patients with decompensated cirrhosis 
 
⇒ 90% of the patients were anaemic of whom 14% had severe anaemia with a Hb 
less than 6 g/dL 
⇒ The changes in Hb, RBCcount and Haematocrit parallel each other with 
haemodilution evident at each given level of Hb & RBC count 
⇒ In this study males had a worse Hb, RBC count and haematocrit compared to 
females 
⇒ Patients with an upper GI bleed had significantly lower levels than patients 
without bleed. 
⇒ The average Hb of alcoholic cirrhosis patients was 8.7 g/dL compared to 9.3g/dl 
of non-alcoholic cirrhosis indicating alcohol by itself worsens the haematological 
profile  
⇒ The most common type of anaemia was a normochromic normocytic anemia seen 
in 44% of patients 
⇒ Macrocytic picture was seen in 30% of patients; majority (93%) of whom were 
alcoholics  
⇒ 22% patients had microcytic hypochromic anaemia of which roughly 73% 
patients had an upper GI bleed. One patient had hemochromatosis; further 
evaluation of this patient revealed him to have sideroblastic anemia. Dimorphic 
picture was observed only in 4 % of cases. 
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⇒ Ferritin levels were elevated as the severity of liver disease progressed and was 
shown to be stastically significant 
⇒ Transferrin levels decreased as the severity of liver disease increased showing an 
inverse relation between the two.  
⇒ Interpretation of iron studies revealed that the most common type of anemia was 
anemia of chronic disease seen in 66% of patients. Iron deficiency was seen in 
24% of patients and iron overload seen in 10% of patients. Elevated ferritin levels 
may mask the actual number of cases of iron deficiency; hence soluble transferrin 
receptor levels need to be measured to get a true estimate of iron deficiency. Iron 
overload is seen in alcoholic patients and the one patient with hemochromatosis. 
⇒ 96 % of patients were folate deficient, alcoholics being significantly more 
deficient than non-alcoholic cirrhosis. 
⇒  Vitamin B12 levels were elevated in 68 % of patients and correlated significantly 
with severity of liver disease. 
⇒ 44 % of patients had a normal WBC count. 26 % had low counts below 4000. 
Only 16% of patients had a count above 12000 of which 50% had spontaneous 
bacterial peritonitis. 
⇒ 50 % of patients had thrombocytopenia. 
⇒ The severity of thrombocytopenia had good correlation with spleen size 
⇒ The average platelet count of patients with an upper GI bleed was 92000 
compared to 1.2 lakh to those without an upper GI bleed; suggesting other factors 
such functional platelet defects may play a role as well. These need to be 
confirmed with platelet functional studies. 
⇒ Bleeding time was prolonged only in 12 % of patients with thrombocytopenia 
indicating BT as an insensitive test of platelet number and function. 
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⇒ The PT-INR was elevated in 72 % of patients, of which 12 % also had an elevated 
aPTT. However only 25 % of patients with a prolonged PT-INR had upper GI 
bleed indicating other factors such as a rebalanced hemostatic system at work, 
however this needs to be confirmed with more extensive studies. This result 
underlines the fact that clinical status of the patient and not lab values have to be 
treated, when correcting coagulopathy in a patient with cirrhosis. 
 
 From this study we can conclude that various haematological alterations are 
very common in cirrhosis patients that needs to be identified and corrected early to 
reduce morbidity and mortality. 
 
POTENTIAL FUTURE STUDIES 
 
1. Erythropoietin, Thrombopoietin levels and adequacy of bone marrow response 
in decompensated chronic liver disease. 
2. Functional abnormalities of WBC in decompensated chronic liver disease 
3. Functional platelet abnormalities in chronic liver disease 
4. Assessment of individual procoagulant and anticoagulant factors in 
decompensated chronic liver disease. 
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PROFORMA 
Name Age Sex IP No. 
Occupation Address 
Presenting complaints 
History of present illness 
Jaundice Pedal edemaAscites  
Abdominal painNausea Vomiting  
FeverHemetemesis/MelenaLOC/Fits/Confusion 
OliguriaChest painConstipation/diarrhoea 
Other symptoms 
Past H/o. 
DiabetesJaundice 
Hypertension Trauma 
Ischemic heart disease Blood transfusion 
Tuberculosis Seizures/involuntary movements 
Bronchial asthma Needle prick 
Chronic kidney disease Surgery 
Malignancy Drugs 
Personal H/o. 
Diet 
Marriage statusSmoker 
AlcoholIv drug abuseSexual history 
Family H/o 
CLDWilson'sHealth of members of family 
 
Clinical examination 
General examination 
Built Clubbing 
Nourishment Cyanosis 
Conscious    Pedal edema 
Oriented     Lymphadenopathy 
AnaemiaJaundice 
Stigmata of CLD: 
Face                                 Hands 
TelengectasiaWhite nails 
Xanthelasma                Palmar erythema 
KF ring                           Duputyren's contracture 
Parotid enlargement 
Paper money skin 
Loss of eye brows 
Jaundice              
Endocrine                      Skin 
GynaecomastiaSpider nevi 
Testicular atrophy       scanty body hairSlate gray pigmentation 
 Scratch marks 
Vital signs 
PulseBlood pressureTemperatureRespiratory rate 
Systemic examination 
CVS 
RS 
CNS: Level of consciousnessFlapping tremorsPlantar reflex Constructional 
apraxia 
ABDOMEN:  
Ascites    Divarication of recti 
Liver     Umbilical hernia 
Splenomegaly 
Dilated veins over abdomenHernia and Hydrocele 
Investigations 
Blood  
TC                                  Liver function test 
DC   S. Bilirubin 
ESR                                SGOT 
HbSGPT 
RBC Count                  SAP  Total protein / Albumin 
PCV  
MCV MCHMCHC 
Platelet count 
Sugar      Blood ureaCreatinine Sodium Potassium 
BT  PT-INR -                       APTT 
Peripheral smear for blood picture 
Reticulocyte count 
Ascitic fluid: 
Biochemical analysisCytologyCell countsFluid C/s 
Chest X-rayECG in all leadsUltrasound abdomen and pelvis 
 
Viral markers 
HBS Ag, Anti HCV antibody 
USG ABDOMENUGI ENDOSCOPY 
 
Iron studies                                 Folate levelsB12 level – 
Serum iron 
Ferritin 
Transferrin  
Transferrin saturation 
TIBC 
 
Measure 1 point 2 points 3 points 
Total bilirubin,(mg/dl) (</=2) (2-3)  (>3) 
Serum albumin, g/l >35 28-35 <28 
PT INR <1.7 1.71-2.30 > 2.30 
Ascites None Mild 
Moderate to 
Severe 
Hepatic 
encephalopathy 
None 
Grade I-II (or suppressed 
with medication) 
Grade III-IV (or 
refractory) 
Total score -  
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1 Marimuthu 44243 32 M yes yes no yes 3 no yes
Alcoholic Liver 
Disease.DCLD, 
Portal HTN,Hepatic 
Encephalopathy
7.8 12400 83/15/2 2.8 23.3 106.9 39.8 35.5 1.53
Macrocytic 
Blood 
Picture/0,4%
509 32 93 73.2 34.40% ACD 2.27 1748 25.9/2.09 7 40 112 14 8 6 92 380 158 7.7 3 4.7 SEVERE II 12
2 Parvathy 45567 45 F yes yes yes no 9 no no
DCLD, portal 
hypertension, 
hypersplenism, 
autoimmune, 
UGI bleed.
4.1 3800 64/27/9 1.9 15.1 74.8 20.3 27.2 0.25
hypochromic 
microcytic 
cells with 
reduced 
platelets
16.9 28 325 256 8.70% IDA 3.18 234 15.6/1.3 10 30 160 3 1.8 1.2 86 50 72 7.1 3 4.1 MILD 0 9
3 Govindan 4485 50 M yes yes no yes 2 yes yes
Alcoholic liver 
disease, DCLD, 
portal 
hypertension, 
hepatic 
encephalopathy, 
HRS
5.5 20800 84/16 2.4 18 84 25.6 30.6 3.19
normocytic 
normochromi
c cells/0.7
1650 110 111 87 10% ACD 1.59 >2000 2.46 4 28 90 25 20 5 15 36 46 10.6 3.5 7.1 SEVERE II 12
4 Murugan 47221 52 M yes no no no 4 yes no
Alcoholic liver 
disease, DCLD, 
portal 
hypertension
5.6 14800 80/20 2.3 19 119 37.2 37.1 0.98
macrocytic 
picture / 0.6%
520 30 90 110 30% ACD 1.37 1001 1.2 6 28 168 9.2 5.6 3.2 30 46 110 5.9 1.6 4.3 SEVERE 0 12
5 Mupidathi 57314 58 M no no yes yes 2 yes no
DCLD, HBsAg 
positive, portal 
hypertension, 
hepatic 
encephalopathy, 
UGI bleed
7.2 3600 70/30 2.7 28 72 26 27 1.6
microcytic 
hypochromic / 
1%
5.5 17 321 178 5.2 IDA 3.51 718 1.1 6 26 280 2.4 1.8 0.6 42 38 82 6.8 3 3.8 MILD I 9
6 Thirviyam 47377 40 M no no yes yes 3 no no
DCLC, ? Cause, 
portal HTN, HE, 
UGI bleed
5.2 4700 50/40/7/3 2.1 16.6 95.6 29.8 32 1.2
normocytic 
normochromi
c anaemia 
with mild 
thrombocytop
enia / 1%
509 32 93 73.2 34.40% ACD 2.2 1748 1.2 4 25 300 2.2 1.1 1.1 48 36 92 5.8 2.8 3 MILD I 9
7 Bhagavathi 87177 65 F no no no no 2 yes no
DCLD, hepatitis 
B, portal HTN
10.1 3800 60/36/4 4.1 30 70 24 27 3.8
microcytic 
hypochromic 
cells / 0.8%
20.3 46 387 305 11.80% IDA 3.43 1255 1.4 3 30 276 1.2 0.8 0.4 36 38 28 6.2 3 3.2 MILD 0 7
8 Chinnathamb 53817 55 M Yes yes no yes 2 yes yes
Alcoholic liver 
disease, DCLD, 
Portal HTN, HE
10.8 3900 70/30 4.3 36 110 28 30 1.4
macrocytic 
cells with 
target cells 
272 54 77 56.6 ACD 2.1 1418 2.4 5 32 98 4.8 2.8 2 57 30 92 5.8 1.4 4.4 SEVERE II 13
Master Chart
Liver Function TestsIron StudiesComplete Blood Countsymptoms & signs
r
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s
k
 
f
a
c
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9 murugaiah 11456 35 M yes yes no yes 2 no yes
Alcoholic liver 
disease, DCLD, 
Portal HTN, 
HE,SBP
5.4 19300 78/20/2 2.2 15.4 54.5 38.8 35 1.5
macrocytic 
cells with mild 
anisocytosis, 
target cells, 
acanthocytes, 
lecucytosis 
with left shift
322 83 62 48 110% ACD 1.32 633 2.8 3.5 40 90 6 4 2 54 80 92 5.4 2 3.4 SEVERE IV 14
10 havasipandiya 36177 45 M no no no no 2 no yes
Alcoholic  liver 
disease, DCLD, 
Portal HTN
11.2 3400 70/30 4.5 39 58 30 33 2 lac
normocytic 
normochromi
c
1650 70 36 28 ACD 1.24 2000 1.4 2 30 360 3.2 1.2 2 60 66 80 6.2 3.1 3.1 MILD 0 9
11 Hariram 24679 58 M no no no no 5 no yes
ALD, cirrhosis, 
portal HTN
9.1 9100 55/40/5 3.4 29.7 100.3 31.4 32 0.58
macrocytic 
picture with 
poikilocytosis 
/ 0.8%
79.1 40 201 158 41.80% ACD 3.32 1021 6 1.6 30 168 3 2 1 48 46 92 6.8 3 3.8 MILD none 8
12 Ramar 26510 50 M yes yes no yes 3 yes no
DCLD, Hepatits 
B, portal HTN, 
HE
9.8 6000 60/30/10 3.6 30 88 30 31 1.2 lacs
normochromi
c, normocytic 
/ 0.9%
1650 110 111 212 51 ACD 1.59 2000 5 1.8 29 240 4.2 2 2.2 48 46 90 7.1 3.5 3.6 MILD II 10
13 Thangaraj 17671 59 M no  no no no 2 no no
DCLD ? CAUSE. 
Portal HTN
12.2 6200 60/34/6 4.6 34.3 90.4 22.1 35.5 1.52
normochromi
c normocytic 
with few 
hypochromic 
cells / 1%
59 37 168 168 27.7 ACD 4.62 762 4 1.2 54 300 2.1 1 1.1 46 40 87 7.6 3.4 4.2 MILD none 7
14 Sangeetha 42526 38 F no no no no 2 no no
DCLD, 
autoimmmune 
hepatitis, portal 
HTN
12.8 7000 70/30 4.8 40 98 31 33 2.8
normochromi
c nomocytic / 
1%
128.2 66 233 183 28%
normal 
status
5.69 562 4 1.2 26 225 1.6 0.2 1.4 40 40 80 7 3 4 MILD none 6
15 Chandran 47741 40 M yes yes no yes 8 yes yes
ALD, cirrhosis, 
portal HTN, HE
13.3 6000 85/15 4.8 40.6 100.7 33 32.8 0.58
macrocytic 
picture / 1%
310 28 210 170 13.30% ACD 1.26 1000 5 1.3 27 314 4.5 1.5 3 61 208 276 6.7 3 3.7 MILD II 10
16 Pattu 46451 45 M no no yes no 7 no no
DCLD ? CAUSE. 
Portal HTN, UGI 
bleed
7.5 7300 77/12/11 2.6 24.8 72.1 26 27 0.68
microcytic 
hypochromic / 
1.2%
7.4 36 260 156 13.80% IDA 1.1 568 4 1.3 25 218 0.6 0.3 0.3 75 65 471 6.7 3 3.7 MILD none 7
17 Ramalingam 42966 51 M no  no yes yes 2 no yes
ALD, cirrhosis, 
portal HTN, UGI 
bleed, folate and 
iron deficiency
6.7 6100 63/27/10 2.1 23 68.2 19.9 29.1 3.9
dimorphic 
picture / 0.8%
161 36 210 157 17% IDA 1.2 970 5 1.2 28 283 1.3 0.7 0.6 30 37 195 6.2 3 3.2 MILD none 7
18 Kanagaraj 25234 33 M no no no no 3 no no
DCLD, portal 
HTN ? 
Autoimmune
10.6 10300 51/38/11 3.8 32.7 87 28 33 1.2
normochromi
c normocytic / 
1.2%
721 36 240 138 15%
normal 
status
2.5 620 4 1.3 28 312 2 1.4 0.6 37 133 47 5.4 2.2 3.2 MILD none 8
19 marimuthu 26910 39 F no  no no no 4 no no
DCLD, cirrhosis ? 
Cause, portal 
HTN
12.8 7000 70/20/10 5.2 28 92 30 32 1.6
normochromi
c normocytic / 
1.2%
160.9 168 192 157 58%
normal 
status
4.5 721 5 1.2 27 300 1.4 0.7 0.5 40 46 88 6.4 3 3.4 MILD none 7
20 John 53135 42 M yes yes no yes 3 yes yes
ALD, cirrhosis, 
portal HTN, 
grade 2 HE, SBP
10.6 18700 88/10/2 4.3 34.3 98 30.5 30.9 1.25
normochromi
c normocytic 
with reactvive 
neutrophils 
and toxic 
granules
618 36 230 170 18% ACD 3 900 6 1.5 30 314 3.4 1.4 2 62 107 193 7.8 3.3 4.5 MOD II 10
21 Subbulakshm 47781 70 F yes yes yes yes 10 yes no
DCLD, cirrhosis ? 
Cause, portal 
HTN, HE, 
hypersplenism
5 2700 65/35 2.2 21 88 30 33 0.36
normocytic 
normochromi
c , decreased 
platelets / 2%
1200 36 200 143 218% ACD 1.2 1650 12 1.8 36 120 8 3 5 76 38 164 5.4 1.8 3.6 MOD III 14
22 Basheer 97761 56 M no yes no no 7 no yes
DCLD, ALD, 
portal HTN
13.3 6000 65/35 5.4 40.6 106.7 33 37.8 0.62
macrocytic 
picture / 0.6%
300 28 274 190 10% ACD 3.6 834 4 1.6 26 240 4.5 1.5 3 81 66 70 6.3 3 3.3 MILD none 9
23 Ravanan 47777 55 M yes yes yes yes 5 yes no
DCLD, cirrhosis, 
hepatitis C, 
portal HTN, 
massive UGI 
Bleed, HE
5.5 7700 86/14 2.8 18.5 70.2 20.2 24 0.98
microcytic 
hypochromic / 
1.1%
12 30 260 300 10% IDA 1.8 760 4.5 1.6 28 280 0.9 0.3 0.6 70 60 110 6.6 3 3.6 MILD II 9
24 Jagdish 56321 46 M no no yes yes 8 no no
DCLD, cirrhosis ? 
Cause, portal 
HTN, HE, UGI 
bleed
7.5 7300 79/12/9 3.1 24.8 84.1 30.2 34.1 0.56
normochromi
c normocytic / 
0.7%
16 24 200 200 7% IDA 3.2 500 4 1.7 29 210 1.1 0.5 0.6 28 48 104 6.9 3 3.9 MILD II 9
25 Raja 65784 24 M yes no no no 6 no no
DCLD, cirrhosis, 
Hemochromatos
is, portal HTN, 
sideroblastic 
anaemia, DKA
4.8 9800 60/30/10 2.1 26 78 28 27 0.6
microcytic 
hypochromic / 
0.6%
1100 430 450 250 95%
IRON 
OVERLOA
D
4.8 960 5 2.1 31 120 3.2 1 2.2 50 60 92 6.8 3 3.8 MOD II 11
26 Chandran 46452 46 M  no no no yes 2 no yes
ALD, cirrhosis, 
portal HTN, HE
10.8 9000 60/30/10 3.8 28 101.4 35 33 1.6
macrocytic 
picture / 0.6%
601 40 103 86.4 39% ACD 2.8 1450 3 1.6 29 200 1.8 0.8 1 54 68 110 7 3 4 MILD I 8
27 Sivagasan 58521 40 M  no no  no no 3 no no
DCLD, cirrhosis ? 
Cause, portal 
HTN
11.2 7000 70/20/10 4 33 93.2 30 32 1.62
normochromi
c normocytic / 
1%
680 210 300 200 70%
IRON 
OVERLOA
D
3.6 708 6 1.7 28 260 1.4 0.6 0.8 86 80 70 7.1 3 4.1 MILD 0 8
28 Ramalingam 94848 49 M  no no   no no 4 no yes
DCLD, cirrhosis, 
hepatits B, 
alcoholism, 
portal HTN
8.4 4300 68/30/2 2.7 29 86 28 30 0.96
dimorphic 
picture
900 110 216 230 49% ACD 2.4 930 7 1.6 30 158 2 1 1 96 80 110 6.8 3 3.8 MOD II 10
29 Manikandan 56103 62 M yes yes yes yes 3 yes yes
ALD, cirrhosis, 
portal HTN, HE, 
UGI bleed
7.1 5000 70/30 2.1 27 77 26 25 0.82
microcytic 
htpochromic/
0.8%
10 26 325 260 8% IDA 4.5 760 6 1.9 28 140 4.1 2.1 2 48 112 110 7 3 4 MOD III 13
30 Saravanan 52621 41 M yes yes no yes 2 no no
DCLD, cirrhosis ? 
Cause , portal 
HTN, SBP, HE
10.4 16800 84/16 3.4 32 89 28 29 1.78
normochromi
c normocytic 
with 
neutrophilic 
leucocytosis/1
%
1200 116 210 186 55% ACD 5.8 640 4 1.6 25 287 3.1 1 2.1 48 56 116 6.8 2.8 4 MOD I 11
31 velumani 70353 39 M no  no   no no 5 no yes
ALD, cirrhosis, 
portal HTN
11.6 4500 70/30 4.8 36 110 30 32 0.84
macrocytic 
picture / 0.6%
361 54 216 250 21% ACD 2.9 920 4 5 25 160 2.2 1 1.2 46 124 130 7.2 3.2 4 MILD 0 8
32 Jayashankar 94848 52 M no  no   yes no 6 no yes
ALD, cirrhosis, 
portal HTN, UGI 
bleed, 
hypersplenism
6.5 3800 50/40/10 2.1 17.2 73.1 38 26 0.56
microcytic 
hypochromic/
1.2%
12.1 25 329 280 2% IDA 2.6 760 6 9 26 240 1.6 0.8 0.8 54 130 110 6.8 3 2.4 MILD 0 7
33 Muniandi 70352 50 M yes yes no yes 2 no yes
ALD, cirrhosis, 
portal HTN, HE
10.8 3900 0/30/10/1 3.2 34 108 28 30 1.4
macrocytic 
picture, 
targecells 
seen
270 54 76 68 74%
IRON 
OVERLOA
D
1.4 1116 5 1.7 28 168 2.8 0.8 2 47 80 96 6 2.4 3.6 MOD II 11
34 Selvam 90281 63 M yes yes no yes 3 yes yes
ALD, cirrhosis, 
portal 
hypertension, 
SBP, HE
9.8 13400 90/5/5 3.3 28 111 27 28 1.5
macrocytosis, 
anisocytosis, 
target cells, 
acanthocytosi
s, leucocytosis 
with left shift
322 80 264 50 30% ACD 1.4 980 4 2 30 116 3.4 1 2.4 54 30 92 6.8 3 3.8 MOD III 13
35 Muthusamy 30128 50 M no  no   no no 3 no no
Cirrhosis, portal 
HTN ? Cause
9.2 9100 55/40/5 3.1 29.7 100.3 31.2 30 1.4
macrocytosis/
0.8%
79.1 40 201 156 42% ACD 2.4 1021 6 1.6 30 168 2 1 1 48 96 92 6.8 3 3.8 MILD none 8
36 Rajamuthu 72911 45 M no  yes no  yes 2 no yes
DCLD, cirrhosis, 
ALD, portal HTN, 
HE
10.1 6000 60/40 3.5 30 86 30 31 1.2
normochromi
c 
normocytic/1.
1%
1650 110 316 212 33% ACD 1.56 >2000 4 1.8 28 240 3.1 2 1.2 48 46 90 7.1 3.5 3.6 MILD II 10
37 Veeramani 35051 58 M no  yes no  yes 6 yes yes
ALD, cirrhosis, 
portal HTN, HE
12.1 4800 80/20 4.7 41.6 116 34 31.6 0.8
MACROCYTIC 
PICTURE / 1%
310 28 210 170 14% ACD 1.36 1000 5 4.5 27 314 4.5 1.5 3 61 208 276 6.7 3 3.7 MILD II 10
38 Subramanian 37736 46 M no  no   yes no 7 no yes
ALD, cirrhosis, 
PORTAL HTN, 
UGI bleed
7.6 7300 79/12/9 2.6 24.8 70.1 26 27 0.7
micricytic 
hypochromic / 
1%
7.4 36 260 176 14% IDA 1.4 68 4 5 26 218 0.6 0.3 0.3 75 65 471 6.7 3 3.7 MILD none 7
39 Murugan 70149 28 M no  no   no  yes 2 no no
Cirrhosis, portal 
HTN ? Cause, HE
10.1 9300 57/38/5 4.1 32.7 87 28 23 1.1
NORMOCHRO
MIC 
NORMOCYTIC 
/ 1.1%
722 35 240 138 15% ACD 2.5 620 4 1.3 28 312 2 1.4 0.4 37 133 47 5.4 3.6 1.8 MILD none 8
40 Rajamani 50513 46 M yes no  no   yes 2 no yes
ALD, cirrhosis, 
portal HTN ,HE, 
SBP
10.6 15000 90/10 4.2 34.3 88.6 30.5 31 1.25
normochromi
c normocytic 
618 36 240 176 15% ACD 3 900 3 1.5 29 214 2.1 1.1 1 62 50 112 7.8 3.3 4.5 MOD II 11
41 Nalini 44712 32 F no  yes no   no 2 yes no Wilsons disease 9.2 8800 60/40 3.6 38 90 30 37 1.6
normocytic 
normochromi
c cells; few 
spherocytes 
seen
416 56 318 260 18% ACD 2.1 460 2 1.6 285 300 3.1 0.2 2.9 40 180 160 7.6 3 4.6 MILD none 7
42 sunderaajan 51631 58 M yes no   no  yes 6 yes no
cirrhosis liver, 
hepatitis B, 
portal HTN, 
HEPATIC 
ENCEPHALOPAT
HY I
10.6 7100 65/35 4.9 40.6 91 28 30 0.8
normocytic 
normochromi
c cells 
456 63 316 200 20% ACD 4.2 680 8 8 265 116 2.1 0.1 2 40 46 160 6.6 3 3.6 MOD I 10
43 Karuppasamy 17482 52 M yes no  yes yes 4 no no
DCLD, cirrhosis ? 
Cause, portal 
HTN, HE, UGI 
bleed
7.5 4000 60/40 2.4 21.2 68.6 21 23 0.7
microcytic 
hypochromic 
anaemia / 1%
9 80 260 176 12% IDA 2.21 960 4 8.5 30 300 2.2 1 1.2 46 124 130 6.8 3 3.8 MOD II 11
44 Vijay anand 17688 69 M no  no   no   no 4 no yes
Alcoholic liver 
disease, 
Cirrhosis, portal 
HTN
9.8 3200 60/30/10 3.2 36 80 28 30 0.76
normocytic 
normochromi
c anaemia / 
1%
260 150 300 180 50%
IRON 
OVERLOA
D
2.8 760 6 6 27 316 1.8 0.8 1 58 98 100 7.1 3.5 3.6 MILD 0 6
45 Rajeshwari 45451 46 F no  no  no  no 4 no no
cirrhosis liver ? 
Cause, portal 
HTN
10.1 4600 70/28/2 3.6 38 98 29 31 0.88
normocytic 
normochromi
c cells
290 50 350 190 15% ACD 4.6 800 7 10 25 400 1.4 0.7 0.7 46 54 110 6 2.8 3.2 MILD 0 6
46 Arun 50993 51 M yes no  no  yes 6 no yes
ALD, cirrhosis, 
portal HTN, HE
8.8 3200 63/15 3.3 21 102 30 32 0.65
macrocytic 
blood picture 
/ 0.4%
512 36 94 73.2 34% ACD 2.7 1860 4 11 31 116 3.8 1.8 2 92 350 158 7 3 4 MOD II 12
47 Subbiah 51319 45 M no yes yes yes 10 no yes
ALD, cirrhosis, 
portal HTN, UGI 
bleed, HE grade 
II
7.1 3000 60/30/6 2.7 16 74.8 21 27 0.36
microcytic 
hypochromic 
cells with low 
platelets / 
0.5%
16.9 28 325 256 9% IDA 4.1 1286 3.5 13 295 221 3 1.8 1.2 82 80 72 7.1 3 4.1 MILD II 11
48 Surya 67651 60 M yes no no  yes 8 no yes
DCLD, cirrhosis, 
hepatitis B, 
portal HTN, 
alcoholism, HE
8.7 2800 70/25/5 2.8 28 91 28 28 0.3
normocytic 
normochromi
c cells / 0.8%
1240 30 240 150 13% ACD 2.8 1690 6 12 28 160 2.4 1 1.4 28 70 96 6.8 3 3.8 MOD III 12
49 Swaminathan 67743 48 M no no no  yes 4 no no
cirrhosis ? Cause 
? NASH, portal 
HTN, HE
9.2 4500 80/20 3.3 32 89 26 28 0.8
normocytic 
normochromi
c cells / 0.8%
280 60 180 100 30% ACD 4.2 980 4 6 285 216 1 0.5 0.5 64 90 160 6.8 2.8 4 MILD I 10
50 Badri 56 M yes yes no yes 7 no yes
ALD, cirrhosis, 
portal HTN, HE
8.8 3800 80/20 3.1 32 110 25 28 0.46
MACROCYTIC 
PICTURE
860 40 240 150 17% ACD 2.8 1500 6 14 295 124 3.6 2 1.6 88 110 140 7 3 4 MOD III 13
KEY TO MASTER CHART 
 
 
Hb – Haemoglobin 
TC  –  Total count 
DC  –  Differential count 
PLT  –  platelet 
PCV  – packed cell volume 
MCV  –  mean corpuscular volume 
MCH  –  mean corpuscular haemoglobin 
MCHC – mean corpuscular haemoglobin concentration 
TIBC  –  total iron binding capacity 
T Sat  –  transferrin saturation 
BT  –  bleeding time 
PT-INR  –  Prothrombin time - International Normalized Ratio 
APTT  –  activated partial thromboplastin time 
TB  –  total bilirubin 
DB  –  direct bilirubin 
IB  –  indirect bilirubin 
SGOT  –  serum glutamate oxalate transferase 
SGPT –  serum glutamate Pyruvate transferase 
ALP  –  alkaline phosphatase 
TP  –  total protein 
Alb  –  albumin 
Glob – globulin 
 
